Mycoplasma Diagnostics Market By Product Type (PCR-Based Diagnostics, Serological Tests, Culture-Based Diagnostics, Immunological Tests), By Test Type (Conventional Tests, Automated Tests), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Mycoplasma Diagnostics Market was valued at USD 1.1 billion in 2024-e and will surpass USD 1.6 billion by 2030; growing at a CAGR of 6.8% during 2025 - 2030.

The Mycoplasma diagnostics market is growing rapidly due to increasing awareness about mycoplasma infections and the importance of accurate diagnosis for effective treatment. Mycoplasma, a type of bacteria without a cell wall, is responsible for a variety of respiratory, urogenital, and other infections. The diagnostic methods for detecting mycoplasma include PCR-based diagnostics, serological tests, culture-based diagnostics, and immunological tests. With the rise in infectious diseases and an increased focus on rapid and precise diagnostics, the demand for advanced diagnostic tools has surged.

The market is also driven by the adoption of advanced technologies such as PCR-based diagnostics and automated test systems, which provide faster and more accurate results. The increasing prevalence of mycoplasma-related infections and the growing need for efficient diagnostics in healthcare settings further support market expansion. In addition, ongoing research and technological advancements in diagnostic tools are anticipated to accelerate the growth of the market.

PCR-Based Diagnostics Product Type is Largest Owing to High Sensitivity and Accuracy

The PCR-based diagnostics subsegment is the largest in the Mycoplasma diagnostics market owing to its high sensitivity and accuracy in detecting mycoplasma infections. PCR (Polymerase Chain Reaction) technology enables the amplification of DNA, allowing for the detection of even low quantities of mycoplasma DNA in clinical samples. This method is particularly advantageous as it provides rapid, specific, and reliable results, which is crucial for the timely treatment of infections. PCR-based diagnostics are widely used in hospitals and diagnostic laboratories for their precision and ability to detect a range of mycoplasma species.

The demand for PCR-based diagnostics is further fueled by the growing emphasis on early detection and personalized treatment. The increasing adoption of this technology in both research and clinical settings is expected to drive the continued dominance of PCR-based diagnostics in the market. As new PCR-based diagnostic kits continue to be developed with improved accuracy and ease of use, their market share is likely to expand.

Automated Tests End-User Segment is Fastest Growing Owing to Enhanced Efficiency

The automated tests end-user segment is the fastest growing in the Mycoplasma diagnostics market owing to the increased demand for high-throughput, efficient, and accurate diagnostic solutions. Automated tests significantly reduce human error, streamline diagnostic workflows, and enable faster processing of large volumes of samples. This is especially important in diagnostic laboratories where there is a growing need to handle increasing patient numbers efficiently. The trend towards automation is also driven by the need for consistent, reproducible results and the ability to handle complex testing procedures with minimal manual intervention.

The growing shift towards automated testing systems is expected to improve diagnostic turnaround times and enhance the overall efficiency of healthcare facilities. Additionally, as technology continues to evolve, automated diagnostic platforms are becoming more user-friendly and cost-effective, further driving their adoption in various healthcare settings.

Diagnostic Laboratories End-User Segment is Largest Owing to High Testing Demand

The diagnostic laboratories end-user segment is the largest in the Mycoplasma diagnostics market due to the high demand for specialized testing services. Diagnostic laboratories play a crucial role in accurately diagnosing mycoplasma infections by offering a wide range of diagnostic methods, including PCR-based diagnostics, serological tests, and culture-based diagnostics. The ability of diagnostic laboratories to process large volumes of samples and provide timely results makes them the preferred choice for testing mycoplasma infections.

With increasing awareness of mycoplasma-related infections and the need for accurate diagnostic tools, diagnostic laboratories are seeing heightened demand for their services. This trend is supported by advances in laboratory technologies that improve testing efficiency and accuracy, further reinforcing the dominance of diagnostic laboratories in the Mycoplasma diagnostics market.

North America Region is Largest Owing to Advanced Healthcare Infrastructure

North America is the largest region in the Mycoplasma diagnostics market owing to its advanced healthcare infrastructure, robust healthcare systems, and high rates of healthcare expenditure. The United States, in particular, is a key contributor to the region’s growth, with a well-established network of hospitals, diagnostic laboratories, and research institutes. North America also benefits from high awareness of mycoplasma infections, facilitating early diagnosis and treatment. Furthermore, the region’s focus on research and development in diagnostics and infectious diseases continues to drive innovation and the adoption of advanced diagnostic technologies.

The region’s favorable regulatory environment and significant investments in healthcare and biotechnology further support the market’s expansion. As demand for more precise and rapid diagnostic tools increases, North America remains at the forefront of the Mycoplasma diagnostics market, with continued growth expected in the coming years.

Leading Companies and Competitive Landscape

Leading companies in the Mycoplasma diagnostics market include major diagnostic technology firms such as Roche, Abbott Laboratories, and Thermo Fisher Scientific. These companies are focusing on expanding their product portfolios through continuous innovation, strategic partnerships, and acquisitions. Their extensive research and development efforts aim to introduce cutting-edge diagnostic solutions that provide faster, more accurate results, which are essential for managing infectious diseases like mycoplasma infections.

The competitive landscape is characterized by a strong focus on technological advancements, with companies investing in the development of automated, PCR-based, and serological diagnostic systems. The market is also seeing the emergence of new players offering specialized diagnostic kits for mycoplasma detection. This highly competitive environment, combined with a rising demand for efficient and accurate diagnostic solutions, is expected to foster further innovation in the Mycoplasma diagnostics market.

Recent Developments:

• In December 2024, Thermo Fisher Scientific launched a new PCR-based diagnostic kit for the rapid detection of mycoplasma pneumoniae.
• In November 2024, Roche Diagnostics expanded its portfolio with a fully automated system for mycoplasma detection in clinical laboratories.
• In October 2024, bioMérieux introduced a next-generation sequencing (NGS) platform for comprehensive mycoplasma identification in research settings.
• In September 2024, Abbott Laboratories received FDA approval for its new serological test designed to detect multiple types of mycoplasma infections.
• In August 2024, Becton Dickinson and Company (BD) launched a new immunological diagnostic system for quicker mycoplasma detection in hospitals.

List of Leading Companies:

• Thermo Fisher Scientific
• Roche Diagnostics
• bioMérieux
• Abbott Laboratories
• QIAGEN
• Becton Dickinson and Company (BD)
• Hologic, Inc.
• Danaher Corporation
• Cepheid
• Agilent Technologies
• PerkinElmer
• Thermo Fisher Scientific
• Promega Corporation
• Merck KGaA
• Bio-Rad Laboratories

Report Scope: